| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways |
| Creator | Rouanne et al. |
| Author | Mathieu Rouanne |
| Author | Nadine Houédé |
| Author | Alexandra Masson-Lecomte |
| Author | Pierre Colin |
| Author | Géraldine Pignot |
| Author | Stéphane Larré |
| Author | Evanguelos Xylinas |
| Author | Morgan Rouprêt |
| Author | Yann Neuzillet |
| Abstract | PURPOSE: Over the past 3 decades, no major treatment breakthrough has been reported for advanced bladder cancer. Recent Food and Drug Administration (FDA) approval of five immune checkpoint inhibitors in the management of advanced bladder cancer represent new therapeutic opportunities. This review examines the available data of the clinical trials leading to the approval of ICIs in the management of metastatic bladder cancer and the ongoing trials in advanced and localized settings. METHODS: A literature search was performed on PubMed and ClinicalTrials.gov combining the MeSH terms: 'urothelial carcinoma' OR 'bladder cancer', and 'immunotherapy' OR 'CTLA-4' OR 'PD-1' OR 'PD-L1' OR 'atezolizumab' OR 'nivolumab' OR 'ipilimumab' OR 'pembrolizumab' OR 'avelumab' OR 'durvalumab' OR 'tremelimumab'. Prospectives studies evaluating anti-PD(L)1 and anti-CTLA-4 monoclonal antibodies were included. RESULTS: Evidence-data related to early phase and phase III trials evaluating the 5 ICIs in the advanced urothelial carcinoma are detailed in this review. Anti-tumour activity of the 5 ICIs supporting the FDA approval in the second-line setting are reported. The activity of PD(L)1 inhibitors in the first-line setting in cisplatin-ineligible patients are also presented. Ongoing trials in earlier disease-states including non-muscle-invasive and muscle-invasive bladder cancer are discussed. CONCLUSIONS: Blocking the PD-1 negative immune receptor or its ligand, PD-L1, results in unprecedented rates of anti-tumour activity in patients with metastatic urothelial cancer. However, a large majority of patients do not respond to anti-PD(L)1 drugs monotherapy. Investigations exploring the potential value of predictive biomarkers, optimal combination and sequences are ongoing to improve such treatment strategies. |
| Publication | World Journal of Urology |
| Volume | 36 |
| Issue | 11 |
| Pages | 1727-1740 |
| Date | Nov 2018 |
| Journal Abbr | World J Urol |
| Language | eng |
| DOI | 10.1007/s00345-018-2332-5 |
| ISSN | 1433-8726 |
| Short Title | Development of immunotherapy in bladder cancer |
| Library Catalog | PubMed |
| Extra | PMID: 29855698 |
| Tags | AFU, Biomarkers, Bladder cancer, Carcinoma, Transitional Cell, clinic, CTLA-4, CTLA-4 Antigen, Disease-Free Survival, Female, Humans, Immune checkpoint inhibitors, Immunologic Factors, Immunotherapy, Male, Molecular Targeted Therapy, PD-1, PD-L1, Prognosis, Programmed Cell Death 1 Receptor, Risk Assessment, Survival Analysis, Treatment Outcome, Urinary Bladder Neoplasms, Urothelial cancer |
| Date Added | 2019/10/10 - 10:48:39 |
| Date Modified | 2019/10/24 - 17:35:59 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
